-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Nuochengjianhua (09969.HK) issued an announcement, and the Drug Evaluation Center (CDE) approved the launch of a phase III clinical trial of obutinib to treat systemic lupus erythematosus (SLE). Backed by strong data from the phase IIb clinical trial, the phase III study will evaluate the 75 mg dosing regimen once a day.

Zhitongcaijing·12/14/2025 10:49:01
Listen to the news
Zhitong Finance App News, Nuochengjianhua (09969.HK) issued an announcement, and the Drug Evaluation Center (CDE) approved the launch of a phase III clinical trial of obutinib to treat systemic lupus erythematosus (SLE). Backed by strong data from the phase IIb clinical trial, the phase III study will evaluate the 75 mg dosing regimen once a day.